Steward Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Steward Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$6K	Buy	+72	New	+$6.41K	﹤0.01%	532
2023 Q2	–	Sell	-74	Closed	-$7K	–	527
2023 Q1	$7K	Buy	74 +41	+124%	+$4.25K	﹤0.01%	240
2022 Q4	$3K	Buy	+33	New	+$3.1K	﹤0.01%	247
2022 Q3	–	Sell	-18	Closed	-$1K	–	232
2022 Q2	$1K	Buy	+18	New	+$1.43K	﹤0.01%	675

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Steward Financial Group's BMRN Position: Q3 2023 in Review

Steward Financial Group opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2023: 72 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #532 among its holdings. This is a return to the name: Steward Financial Group previously reported a position in BMRN as recently as Q1 2023.

Steward Financial Group first reported a position in BMRN in Q2 2022 and has held it in 4 quarters since. The position peaked at $7K in Q1 2023. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Steward Financial Group held 72 shares of BioMarin Pharmaceuticals worth $6K as of Q3 2023.
BioMarin Pharmaceuticals was a new Steward Financial Group position in Q3 2023.
BioMarin Pharmaceuticals made up ﹤0.01% of Steward Financial Group's portfolio in Q3 2023, its #532 holding.
Steward Financial Group first reported a position in BioMarin Pharmaceuticals in Q2 2022 and has held it in 4 quarters since.
Steward Financial Group's BioMarin Pharmaceuticals position peaked at $7K in Q1 2023.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Steward Financial Group's 13F filing for Q3 2023, filed 23 Oct 2023.